This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Everything You Need to Know About Biotech M&A in a Single Chart

You're looking at a chart of mergers-and-acquisition activity for the biotech sector going back to 2000. The chart was put together and published by BioCentury recently. ISI Group analyst Mark Schoenebaum shared the M&A chart with clients today, and I'm sharing it with you.

I don't have anything profound to say about the M&A activity trends, other than noting the number of public acquisitions and deal value increased in 2013 over 2012. Both years fell significantly below 2011 M&A deal flow.

There was some concern raised last year about significantly higher biotech valuations having a negative effect on M&A activity. Simply put: Acquirers might find takeout prices of their favored targets too high to justify. [Remember the rumors last year of Roche  (ROG) wanting to buy Alexion Pharma  (ALXN) but being turned off by the required price.]

Well, the M&A numbers from 2013 don't seem to suggest a significant slowdown in deal flow, so perhaps that bodes well for continued higher trend in 2014.

Here's what the analysts at J.P. Morgan had to say about biotech M&A in 2014:

Regarding M&A, we anticipate that the uptick in higher-profile activity (Onyx, ViroPharma, Algeta) in 2H13 could extend into 2014 as pharma companies continue to seek out bolt-on deals (facilitated by plush pharma balance sheets and more mature biotech pipelines). This type of tailwind may be necessary for biotech to once again significantly outperform the broader markets.

My personal takeout predictions for 2014 are Regeneron Pharma (REGN - Get Report), Cempra (CEMP - Get Report), NPS Pharma (NPSP), Clovis Oncology (CLVS) and Halozyme (HALO - Get Report). Throw in Biomarin Pharma (BMRN - Get Report), too. Will deals for these companies actually happen? I have no clue.

-- Reported by Adam Feuerstein in Boston.  

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
BMRN $130.42 13.00%
CEMP $32.40 4.50%
CLVS $73.34 1.60%
HALO $14.00 5.20%
REGN $456.47 1.80%


DOW 17,684.94 +6.71 0.04%
S&P 500 2,058.81 +2.66 0.13%
NASDAQ 4,875.09 +11.7280 0.24%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs